Umbrella Review on Non-Statin Lipid-Lowering Therapy.

Semira Abdi BeshirNadia HussainAsim Ahmed ElnorAmira S A Said

Published in: Journal of cardiovascular pharmacology and therapeutics (2021)

Despite cost limitations, the uptake of PCSK9 inhibitors is increasing. Approval of bempedoic acid alone or in combination with ezetimibe has provided additional oral lipid-lowering drug alternatives to ezetimibe. Various lipid-lowering drug targets are under investigation.

Keyphrases

fatty acid
cardiovascular disease
coronary artery disease
randomized controlled trial
stem cells
systematic review
drug induced